Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Jiheun Han"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Jiheun Han, Yongkil Hong, Youn Soo Lee
J Pathol Transl Med. 2017;51(1):40-48.   Published online December 15, 2016
DOI: https://doi.org/10.4132/jptm.2016.08.31
  • 13,941 View
  • 275 Download
  • 32 Web of Science
  • 34 Crossref
AbstractAbstract PDF
Background
Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells. Immunotherapy targeting these molecules is emerging as a new strategy for the treatment of glioblastoma (GBM). Understanding the relationship between the PD-L1/PD-1 axis and prognosis in GBM patients may be helpful to predict the effects of immunotherapy.
Methods
PD-L1 expression and PD-1–positive tumor infiltrating mononuclear cell (PD-1+tumor infiltrating mononuclear cell [TIMC]) density were evaluated using tissue microarray containing 54 GBM cases by immunohistochemical analysis; the associations with patient clinical outcomes were evaluated.
Results
PD-L1 expression and high PD-1+TIMC density were observed in 31.5% and 50% of GBM cases, respectively. High expression of PD-L1 in tumor cells was an independent and significant predictive factor for worse overall survival (OS; hazard ratio, 4.958; p = .007) but was not a significant factor in disease-free survival (DFS). PD-1+TIMC density was not correlated with OS or DFS. When patients were classified based on PD-1 expression and PD-1+TIMC density, patients with PD-L1+/PD-1+TIMC low status had the shortest OS (13 months, p = .009) and DFS (7 months, p = .053).
Conclusions
PD-L1 expression in GBM was an independent prognostic factor for poor OS. In addition, combined status of PD-L1 expression and PD-1+TIMC density also predicted patient outcomes, suggesting that the therapeutic role of the PD-1/PD-L1 axis should be considered in the context of GBM immunity.

Citations

Citations to this article as recorded by  
  • Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists
    Giuseppe Broggi, Giuseppe Angelico, Jessica Farina, Giordana Tinnirello, Valeria Barresi, Magda Zanelli, Andrea Palicelli, Francesco Certo, Giuseppe Barbagallo, Gaetano Magro, Rosario Caltabiano
    Pathology - Research and Practice.2024; 254: 155144.     CrossRef
  • Treatment advances in high-grade gliomas
    Xi Chen, Yi Cui, Liqun Zou
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors
    Joshua R. D. Pearson, Carles Puig-Saenz, Jubini E. Thomas, Lydia D. Hardowar, Murrium Ahmad, Louise C. Wainwright, Adam M. McVicar, Victoria A. Brentville, Chris J. Tinsley, A. Graham Pockley, Lindy G. Durrant, Stephanie E. B. McArdle
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
    Berta Segura-Collar, Sara Hiller-Vallina, Olaya de Dios, Marta Caamaño-Moreno, Lucia Mondejar-Ruescas, Juan M. Sepulveda-Sanchez, Ricardo Gargini
    Acta Neuropathologica Communications.2023;[Epub]     CrossRef
  • Immunohistochemical Analysis of PD-1 and FOXP3 in Tumor-Infiltrating Lymphocytes in Human Gliomas
    Priyanka Kanagaraj, Archana Balasubramanian, Raveena Suresh, Bhargavi Somasundaram, Sandhya Sundaram, Priyathersini Nagarajan
    Cureus.2023;[Epub]     CrossRef
  • Expression, prognostic significance and therapeutic implications of PD‐L1 in gliomas
    Gayaththri Vimalathas, Bjarne Winther Kristensen
    Neuropathology and Applied Neurobiology.2022;[Epub]     CrossRef
  • PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma
    Carolina Noronha, Ana Sofia Ribeiro, Ricardo Taipa, Dina Leitão, Fernando Schmitt, Joaquim Reis, Cláudia Faria, Joana Paredes
    Journal of Neuro-Oncology.2022; 156(3): 453.     CrossRef
  • Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas
    Makoto Ohno, Shigehisa Kitano, Kaishi Satomi, Akihiko Yoshida, Yasuji Miyakita, Masamichi Takahashi, Shunsuke Yanagisawa, Yukie Tamura, Koichi Ichimura, Yoshitaka Narita
    Journal of Neuro-Oncology.2022; 160(2): 463.     CrossRef
  • The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis
    Xin Guo, Yuelin Zhang, Hengxing Jiao, Xingyu Miao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway
    Xiaoming Wang, Yan Zhang, Jian Zheng, Cuixian Yao, Xiubo Lu
    Cancer Immunology, Immunotherapy.2021; 70(8): 2235.     CrossRef
  • Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
    Kelsey Maddison, Moira C. Graves, Nikola A. Bowden, Michael Fay, Ricardo E. Vilain, Sam Faulkner, Paul A. Tooney
    Oncotarget.2021; 12(21): 2177.     CrossRef
  • A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology
    Mahdi Abdoli Shadbad, Zahra Asadzadeh, Negar Hosseinkhani, Afshin Derakhshani, Nazila Alizadeh, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset
    Huan Wang, Youchao Xiao, Xingguang Ren, Dahai Wan
    Bioengineered.2021; 12(2): 10366.     CrossRef
  • Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma
    Nyall R. London, Lisa M. Rooper, Justin A. Bishop, Haiying Xu, Lydia J. Bernhardt, Masaru Ishii, Christine L. Hann, Janis M. Taube, Evgeny Izumchenko, Daria A. Gaykalova, Gary L. Gallia
    World Neurosurgery.2020; 135: e187.     CrossRef
  • CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
    Joseph A. Flores-Toro, Defang Luo, Adithya Gopinath, Matthew R. Sarkisian, James J. Campbell, Israel F. Charo, Rajinder Singh, Thomas J. Schall, Meenal Datta, Rakesh K. Jain, Duane A. Mitchell, Jeffrey K. Harrison
    Proceedings of the National Academy of Sciences.2020; 117(2): 1129.     CrossRef
  • Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence
    Kyoung Su Sung, Tae Hoon Roh, Ju Hyung Moon, Eui Hyun Kim, Seok-Gu Kang, Se Hoon Kim, Jong Hee Chang
    World Neurosurgery.2020; 135: e459.     CrossRef
  • Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma
    Chang Shu, Qingguo Li
    Critical Reviews in Oncology/Hematology.2020; 151: 102965.     CrossRef
  • PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis
    Chengcheng Hao, Gang Chen, Huishan Zhao, Yan Li, Jianxin Chen, Hongmei Zhang, Shan Li, Yuze Zhao, Feng Chen, Wenbin Li, Wen G. Jiang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook
    Patrick C. Gedeon, Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, John H. Sampson
    Expert Review of Clinical Pharmacology.2020; 13(10): 1147.     CrossRef
  • Current clinical management of elderly patients with glioma
    Alessia Pellerino, Francesco Bruno, Valeria Internò, Roberta Rudà, Riccardo Soffietti
    Expert Review of Anticancer Therapy.2020; 20(12): 1037.     CrossRef
  • The Prognostic and Therapeutic Value of PD-L1 in Glioma
    Ruo Qiao Chen, Feng Liu, Xin Yao Qiu, Xiao Qian Chen
    Frontiers in Pharmacology.2019;[Epub]     CrossRef
  • Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
    Xin Wang, Gaochao Guo, Hui Guan, Yang Yu, Jie Lu, Jinming Yu
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma
    Xiao Shi, Peng-Cheng Yu, Bo-Wen Lei, Cui-Wei Li, Yan Zhang, Li-Cheng Tan, Rong-Liang Shi, Jie Wang, Ben Ma, Wei-Bo Xu, Xiao Wang, Jia-Qian Hu, Nai-Si Huang, Wen-Jun Wei, Yu Wang, Tong-Zhen Chen, Yu-Long Wang, Qing-Hai Ji
    Thyroid.2019; 29(9): 1269.     CrossRef
  • The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling
    Ruo Qiao Chen, Xiao Hong Xu, Feng Liu, Chun Yang Li, Yuan Jun Li, Xiang Rui Li, Guo Yong Jiang, Feng Hu, Di Liu, Feng Pan, Xin Yao Qiu, Xiao Qian Chen
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker
    Yong Ju Lee, Yoon Woo Koh, Sun Och Yoon, Hyang Joo Ryu, Hye Ryun Kim, Hyang Ae Shin
    Korean Society for Head and Neck Oncology.2019; 35(1): 13.     CrossRef
  • Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
    Kyu Sang Lee, Kyoungyul Lee, Sumi Yun, Seyoung Moon, Yujun Park, Jung Ho Han, Chae-Yong Kim, Hye Seung Lee, Gheeyoung Choe
    Journal of Neuro-Oncology.2018; 136(3): 453.     CrossRef
  • Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
    Hyo Jung An, Gyung Hyuck Ko, Jeong-Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Jin Pyeong Kim, Eun Jung Jung, Dae Hyun Song
    Journal of Pathology and Translational Medicine.2018; 52(1): 9.     CrossRef
  • Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
    Michele Porcu, Cinzia Solinas, Paolo Garofalo, Evandro de Azambuja, Mario Scartozzi, Karen Willard-Gallo, Matthias Preusser, Luca Saba
    Critical Reviews in Oncology/Hematology.2018; 126: 135.     CrossRef
  • The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma
    Fumihiko Sato, Jun Akiba, Akihiko Kawahara, Yoshiki Naito, Takeharu Ono, Yorihiko Takase, Kazuya Murata, Hideyuki Abe, Tomohiko Yamaguchi, Hiroaki Miyoshi, Yushi Abe, Yutaro Mihara, Masahiko Tanikawa, Momoko Akashi, Hirofumi Kurose, Hirohito Umeno, Hirohi
    Journal of Oral Pathology & Medicine.2018; 47(7): 683.     CrossRef
  • Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
    Dwight Owen, Benjamin Chu, Amy M. Lehman, Lakshmanan Annamalai, Jennifer H. Yearley, Konstantin Shilo, Gregory A. Otterson
    Journal of Thoracic Oncology.2018; 13(8): 1204.     CrossRef
  • PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
    Noah Frydenlund, Meera Mahalingam
    Human Pathology.2017; 66: 13.     CrossRef
  • Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
    Russell Maxwell, Christopher M. Jackson, Michael Lim
    Current Treatment Options in Oncology.2017;[Epub]     CrossRef
  • Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy
    Joshua Bernstock, Daniel Ye, Florian Gessler, Luca Peruzzotti-Jametti, Mark Gilbert, Yves Pommier, Stefano Pluchino, Ichiro Nakano, John Hallenbeck
    Matters.2017;[Epub]     CrossRef
  • Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
    Song Xue, Man Hu, Peifeng Li, Ji Ma, Li Xie, Feifei Teng, Yufang Zhu, Bingjie Fan, Dianbin Mu, Jinming Yu
    Oncotarget.2017; 8(30): 49702.     CrossRef
Brief Case Report
Mucosal Schwann Cell Hamartoma in Colorectal Mucosa: A Rare Benign Lesion That Resembles Gastrointestinal Neuroma
Jiheun Han, Yosep Chong, Tae-Jung Kim, Eun Jung Lee, Chang Suk Kang
J Pathol Transl Med. 2017;51(2):187-189.   Published online August 25, 2016
DOI: https://doi.org/10.4132/jptm.2016.07.02
  • 10,094 View
  • 203 Download
  • 6 Web of Science
  • 12 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Schwann Cell Hamartoma Presenting as a Colonic Polyp: A Rare Case Report With a Literature Review
    Faryal Altaf, Nismat Javed, Haider Ghazanfar, Anil Dev
    Cureus.2024;[Epub]     CrossRef
  • Mucosal Schwann Cell Hamartoma Mimicking a Colon Polyp: Pathologic Insights
    Marissa Krizelda Santos, Kathleen Adryon Tan
    PJP.2024;[Epub]     CrossRef
  • Multiple non-polypoid mucosal Schwann cell hamartomas presenting as edematous and submucosal tumor-like lesions: a case report
    Takeshi Okamoto, Takaaki Yoshimoto, Katsuyuki Fukuda
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Mucosal Schwann Cell Hamartoma of the Gall Bladder
    Kanika Sharma, Anjan Kumar Dhua, Prabudh Goel, Vishesh Jain, Devendra Kumar Yadav, Prashant Ramteke
    Journal of Indian Association of Pediatric Surgeons.2021; 26(3): 182.     CrossRef
  • Mucosal Schwann Cell Hamartoma in sigmoid colon – A rare case report and review of literature
    Xiuyan Feng, Hongzhi Xu, Nestor Dela Cruz
    Human Pathology: Case Reports.2020; 19: 200337.     CrossRef
  • Spindle cell proliferations of the sigmoid colon, rectum and anus: a review with emphasis on perineurioma
    Patrice Grech, John B Schofield
    Histopathology.2020; 76(3): 342.     CrossRef
  • Mucosal Schwann cell hamartoma of the gastroesophageal junction: A series of 6 cases and comparison with colorectal counterpart
    Yuan Li, Pouneh Beizai, John W. Russell, Lindsey Westbrook, Arash Nowain, Hanlin L. Wang
    Annals of Diagnostic Pathology.2020; 47: 151531.     CrossRef
  • Mucosal Schwann Cell Hamartoma Presenting as Diffuse Fine Nodularities
    Han Beol Jang, Jong Ok Kim, Sang-Bum Kang
    The Korean Journal of Gastroenterology.2020; 76(3): 171.     CrossRef
  • A case of Schwann cell hamartoma of the tongue
    Saya TAKIKAWA, Shigeo TANAKA, Masamichi KOMIYA, Masaaki SUEMITSU, Tadahiko UTSUNOMIYA, Kayo KUYAMA
    Japanese Journal of Oral and Maxillofacial Surgery.2020; 66(12): 601.     CrossRef
  • Hamartoma de células de Schwann mucoso: revisión de una entidad descrita recientemente
    Francisco García-Molina, José Antonio Ruíz-Macia, Joaquin Sola
    Revista Española de Patología.2018; 51(1): 49.     CrossRef
  • Neural and neurogenic tumours of the gastroenteropancreaticobiliary tract
    Aoife J McCarthy, Dipti M Karamchandani, Runjan Chetty
    Journal of Clinical Pathology.2018; 71(7): 565.     CrossRef
  • Case of colonic mucosal Schwann cell hamartoma and review of literature on unusual colonic polyps
    JayaKrishna Chintanaboina, Kofi Clarke
    BMJ Case Reports.2018; : bcr-2018-224931.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP